Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma.
chemoradiotherapy
induction chemotherapy
meta-analysis
nasopharyngeal neoplasms
Journal
Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941
Informations de publication
Date de publication:
Historique:
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
23
11
2021
Statut:
ppublish
Résumé
Induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone are both standard treatment regimens for managing locally advanced nasopharyngeal carcinoma. However, the results of comparisons between them in clinical trials vary. Therefore, we designed this meta-analysis to illustrate their advantages and disadvantages in patients with locally advanced nasopharyngeal carcinoma. We thoroughly searched the PubMed, EMBASE, and Cochrane Library databases and then merged the effect indicators of hazard ratios and risk ratios using RevMan 5.1. Seven randomized controlled trials totaling 2,319 patients were included in our research. The synthesized results showed that induction chemotherapy plus concurrent chemoradiotherapy improved overall survival (HR = 0.75, 95% CI: 0.63-0.89, Induction chemotherapy plus concurrent chemoradiotherapy improved survival outcomes in patients with locally advanced nasopharyngeal carcinoma versus concurrent chemoradiotherapy. For the weekly cisplatin regimen subgroup, it did not improve remote control or overall survival versus concurrent chemoradiotherapy alone, warranting further clarification.
Identifiants
pubmed: 33511908
doi: 10.1177/1533033821990017
pmc: PMC7871351
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1533033821990017Références
Cancer Treat Rev. 2009 Jun;35(4):345-53
pubmed: 19211192
Oncotarget. 2017 Oct 6;8(55):94117-94128
pubmed: 29212214
PLoS One. 2015 Mar 23;10(3):e0120019
pubmed: 25799566
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):952-60
pubmed: 25832687
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1106-12
pubmed: 27026314
PLoS One. 2014 Oct 16;9(10):e110765
pubmed: 25329593
Chin J Cancer. 2017 Nov 9;36(1):90
pubmed: 29122009
Cancer Lett. 2016 Apr 28;374(1):22-30
pubmed: 26828135
Tumour Biol. 2016 Apr;37(4):4429-38
pubmed: 26499947
Int J Cancer. 2019 Jul 1;145(1):295-305
pubmed: 30613964
N Engl J Med. 2019 Sep 19;381(12):1124-1135
pubmed: 31150573
Am J Clin Oncol. 2014 Feb;37(1):63-9
pubmed: 23111356
Eur J Cancer. 2017 Apr;75:14-23
pubmed: 28214653
J Clin Oncol. 1998 Apr;16(4):1310-7
pubmed: 9552031
Radiother Oncol. 2016 Feb;118(2):244-50
pubmed: 26705681
Ann Oncol. 2015 Jan;26(1):205-211
pubmed: 25355717
Lancet Oncol. 2012 Feb;13(2):163-71
pubmed: 22154591
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Eur J Cancer. 2019 Sep;119:87-96
pubmed: 31425966
Clin Oncol (R Coll Radiol). 2020 Apr;32(4):238-249
pubmed: 31813661
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Chin J Cancer Res. 2018 Feb;30(1):51-60
pubmed: 29545719
JAMA Netw Open. 2019 Oct 2;2(10):e1913619
pubmed: 31626318
Clin Cancer Res. 2018 Feb 1;24(3):648-658
pubmed: 29030355
Ther Adv Med Oncol. 2019 Mar 21;11:1758835919833863
pubmed: 30923578
Ann Oncol. 2018 Mar 1;29(3):731-736
pubmed: 29236943
Br J Cancer. 2013 Dec 10;109(12):2987-97
pubmed: 24149175
Ann Oncol. 2012 Feb;23(2):427-35
pubmed: 21525406
J Natl Compr Canc Netw. 2017 Jul;15(7):913-919
pubmed: 28687579
Radiother Oncol. 2018 Oct;129(1):10-17
pubmed: 29555182
Ann Oncol. 2018 Sep 1;29(9):1972-1979
pubmed: 30016391